@article{f21cb12276224f248c893dabfb353ad3,
title = "Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study",
abstract = "Little is known about the challenging treatment of pediatric patients with hemophilia B and inhibitors due to disease rarity. We describe three patients diagnosed in childhood and followed up to 9 years. All three had allergic reactions to Factor IX, but two were later safely treated for bleeding episodes with activated prothrombin complex concentrates (APCC = FEIBA). The third was given only recombinant activated Factor VIIa. Based on ex vivo thrombin generation analysis, a new alternative treatment of combined bypassing agents was administered for bleeding episodes and several minor surgical procedures with no treatment-associated adverse events or thrombosis.",
keywords = "FEIBA, hemophilia B, inhibitor, rFVIIa, thrombin generation",
author = "Barg, {Assaf Arie} and Sarina Levy-Mendelovich and Einat Avishai and Rima Dardik and Mudi Misgav and Gili Kenet and Tami Livnat",
note = "Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = dec,
doi = "10.1002/pbc.27381",
language = "אנגלית",
volume = "65",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "12",
}